Cusatuzumab

Cusatuzumab (OV-1001, JNJ-74494550, ARGX-110) is a monoclonal antibody developed by OncoVerity. Its target is CD70. ClinicalTrials.gov describes the intervention as: Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in acute myeloid leukaemia. The largest, NCT06384261, plans to enrol 140 participants with primary completion expected 2027-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.